Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis

Author:

Yang Ping1,Cai Qing‐qing2ORCID,Zhang Wei3ORCID,Liu Shuo‐zi1,Liu Hui4,Sun Xiu‐hua5,Dong Yu‐jun6ORCID,Xiao Xiu‐bin7,Wang Jing‐wen8,Li Zhen‐ling9,Huang Wen‐rong7,Li Li‐hong10,Bao Hui‐zheng11,Yang Wei12,Wang Ya‐lan13,Wang Shu‐ye14,He Juan15,Li Xiao‐ling16,Liu Ai‐chun17,Jing Hong‐mei1ORCID

Affiliation:

1. Department of Hematology Peking University Third Hospital Beijing China

2. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China

3. Department of Hematology Peking Union Medical College Hospital Beijing China

4. Department of Hematology Beijing Hospital Beijing China

5. Department of Medical Oncology The Second Hospital of Dalian Medical University Dalian China

6. Department of Hematology Peking University First Hospital Beijing China

7. Senior Department of Hematology The 5th Medical Center of PLA General Hospital Beijing China

8. Department of Hematology Beijing Tongren Hospital Beijing China

9. Department of Hematology China‐Japan Friendship Hospital Beijing China

10. Department of Hematology Beijing Tsinghua Changgung Hospital Beijing China

11. Department of Medical Oncology Jilin Cancer Hospital Changchun China

12. Department of Hematology Shengjing Hospital of China Medical University Shenyang China

13. Department of Medical Oncology Baotou Cancer Hospital Baotou China

14. Department of Hematology The First Hospital of Harbin Medical University Harbin China

15. Department of Hematology The First Hospital of China Medical University Shenyang China

16. Department of Medical Oncology Liaoning Cancer Hospital & Institute Shenyang China

17. Department of Hematology and Lymphatic Medicine Harbin Medical University Cancer Hospital Harbin China

Abstract

AbstractBackgroundMantle cell lymphoma (MCL) is an uncommon heterogeneous subtype of B cell non‐Hodgkin lymphoma, and clinical features in MCL appear regional characteristics. MCL treatment opinions are not uniform between countries or regions within Asia and China, and Asian patient‐specific data for MCL treatment are fewer. The study aims to explore the clinical characteristics, treatment patterns and prognosis of MCL patients in China.MethodsA total of 805 patients diagnosed with MCL between April 1999 and December 2019 at 19 comprehensive hospitals in China were included in this retrospective analysis. Kaplan‐Meier method coupled with the log‐rank test was used for univariate analysis, and COX proportional hazards model was used for multivariate analysis (MVA). p < 0.05 was consided statistically significant. All outputs were produced using R version 4.1.0.ResultsThe median age of the cohort was 60.0 years with a male‐to‐female ratio of 3.36:1. Five‐year progression‐free survival (PFS) and overall survival (OS) rates were 30.9% and 65.0%, respectively. High‐intermediate/high‐risk group according to MIPI‐c, without high‐dose cytarabine, lack of Auto‐SCT as consolidation and maintenance treatment and SD/PD in initial treatment remained statistically relevant to poor PFS on MVA, and ki67 ≥50%, B symptoms, high‐intermediate/high risk group according to MIPI‐c, without high‐dose cytarabine, lack of maintenance treatment, SD/PD in initial treatment and relapse/refractory state were independently associated with poorer OS on MVA.ConclusionsFirst‐line high dose cytarabine exposure, auto‐SCT as consolidation therapy obtained survival benefits in Chinese population. Our study further confirmed the value of maintenance treatment and explored the application of new drug treatment and bendamustine in R/R MCL patients.

Funder

Wu Jieping Medical Foundation

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3